Peter Uggowitzer, MD
Family Medicine · Hampstead, MDNPI 1255333274
Payments from drug & device makers
Across 87 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$303
- AbbVie$275
- GSK$262
- Novartis$187
- Novo Nordisk$105
- Pfizer$88
- plus $511 from 13 others
What the payments were for
- Food & beverage$1,730100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $303 |
| AbbVie(2 entities) | 17 | $275 |
| GSK | 15 | $262 |
| Novartis | 5 | $187 |
| Novo Nordisk | 7 | $105 |
| Pfizer | 5 | $88 |
| Dexcom, Inc. | 2 | $87 |
| Topcon Healthcare Solutions, Inc. | 1 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Merck | 5 | $62 |
| Amgen | 4 | $58 |
| Supernus Pharmaceuticals, Inc. | 2 | $42 |
| Insightec,inc | 1 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Galderma Laboratories, L.p. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Shionogi Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,730 in reported general payments places this provider in the 75th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 89 | $105,599 |
| JanuviaSitagliptin Phosphate | 84 | $79,248 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $56,316 |
| FarxigaDapagliflozin Propanediol | 54 | $44,875 |
| OzempicSemaglutide | 32 | $41,775 |
| TradjentaLinagliptin | 24 | $29,933 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $28,402 |
| EntrestoSacubitril/Valsartan | 25 | $22,900 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $19,485 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $11,416 |
| TrintellixVortioxetine Hydrobromide | 11 | $11,137 |
| AlogliptinAlogliptin Benzoate | 15 | $5,889 |
| Valsartan | 135 | $5,532 |
| Novolog FlexpenInsulin Aspart | 14 | $3,220 |
| Amlodipine Besylate | 406 | $2,663 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $88 | $105,59989 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $262 | $84,718102 claims |
| MerckJanuvia | $62 | $79,24884 claims |
| AstraZenecaFarxiga | $303 | $44,87554 claims |
| Novo NordiskOzempic | $105 | $41,77532 claims |
| NovartisEntresto | $187 | $22,90025 claims |
| AbbVieSynthroid | $275 | $1,48319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Hampstead
- Stephen OngOxon Hill$5.9M
- Stephan BartWoodstock$1.7M
- Karen DonaldsonBaltimore$899K
- Rajiv DuaColumbia$765K
- Greg TampusLutherville Timonium$735K
- Louis JacquesBaltimore$522K
- Stephanie MellerOxon Hill$518K
- Sharon ChungGlen Burnie$333K
- Michael ObiefuneBaltimore$291K
- Thomas LawrenceBerlin$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.